| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment ($ in thousands):
| | | | | | Pharmaceutical
and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | Year Ended December 31, 2017 | | Products
Sales | | Product
Development | | National | | Consolidated | | | Net Revenue | | $ | 15,520 | | $ | 1,725 | | $ | 170,339 | | $ | 187,584 | | | Direct cost of goods | | | (3,658) | | | - | | | - | | | (3,658) | | | Sales and marketing costs | | | (10,410) | | | - | | | - | | | (10,410) | | | Research and development | | | - | | | (52,486) | | | - | | | (52,486) | | | General and administrative | | | (1,140) | | | (39,347) | | | - | | | (40,487) | | | National expenses | | | - | | | - | | | (181,751) | | | (181,751) | | | Segment profit (loss) from operations | | $ | 312 | | $ | (90,108) | | $ | (11,412) | | $ | (101,208) | | | Segment assets | | $ | 9,644 | | $ | 187,941 | | $ | 48,365 | | $ | 245,950 | | | | | | | | Pharmaceutical
and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | Year Ended December 31, 2016 | | Products
Sales | | Product
Development | | National | | Consolidated | | | Net Revenue | | $ | 3,587 | | $ | 2,570 | | $ | 10,323 | | $ | 16,480 | | | Direct cost of goods | | | (790) | | | - | | | - | | | (790) | | | Sales and marketing costs | | | (5,774) | | | - | | | - | | | (5,774) | | | Research and development | | | - | | | (35,134) | | | - | | | (35,134) | | | General and administrative | | | (1,474) | | | (26,755) | | | - | | | (28,229) | | | National expenses | | | - | | | - | | | (12,263) | | | (12,263) | | | Segment loss from operations | | $ | (4,451) | | $ | (59,319) | | $ | (1,940) | | $ | (65,710) | | | Segment assets | | $ | 4,469 | | $ | 115,145 | | $ | 51,117 | | $ | 170,731 | | | | | | | | Pharmaceutical
and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | Year Ended December 31, 2015 | | Products
Sales | | Product
Development | | National | | Consolidated | | | Net Revenue | | $ | 273 | | $ | 590 | | $ | - | | $ | 863 | | | Direct cost of goods | | | - | | | - | | | - | | | - | | | Sales and marketing costs | | | (2,850) | | | - | | | - | | | (2,850) | | | Research and development | | | - | | | (29,810) | | | - | | | (29,810) | | | General and administrative | | | (1,682) | | | (17,052) | | | - | | | (18,734) | | | Segment loss from operations | | $ | (4,259) | | $ | (46,272) | | $ | - | | $ | (50,531) | | | Segment assets | | $ | 1,965 | | $ | 116,542 | | $ | - | | $ | 118,610 | |
|